Avicanna Inc. (TSX: AVCN)

Market Cap	32.92M
Revenue (ttm)	22.07M
Net Income (ttm)	-6.55M
Shares Out	97.60M
EPS (ttm)	-0.07
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	33,000
Open	0.350
Previous Close	0.350
Day's Range	0.350 - 0.370
52-Week Range	0.230 - 0.600
Beta	1.59
Analysts	n/a
Price Target	0.70 (+94.44%)
Earnings Date	Aug 13, 2024

About Avicanna

Avicanna Inc., a commercial-stage biopharmaceutical company, engages in the research and development of evidence-based products for consumer medical and pharmaceutical segments worldwide. The company collaborates with Canadian academic and medical institutions. Its scientific platform includes research and development, and clinical development that leads to the commercialization of approximately twenty products across four main market segments. The company provides medical and wellness products containing cannabidiol, cannabigerol, and tetrahyd...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• CEO: Mr. Aras Azadian B.Econ, Mba
• Country: Canada
• Stock Exchange: Toronto Stock Exchange
• Ticker Symbol: AVCN

Financial Performance

In 2023, Avicanna's revenue was 16.79 million, an increase of 314.82% compared to the previous year's 4.05 million. Losses were -7.89 million, -54.21% less than in 2022.